bioRxiv Science⌕ Search

Biology subjects

Chapel, A.

Publications and source records attributed to Chapel, A..

2 recordsLinked to original sources

P2Y2 purinergic receptor and DNA sensor cGAS dictate ionizing radiation-mediated proinflammatory macrophage activation

The reprogramming of tumor-associated macrophages (TAMs) by radiotherapy is associated with cancer patients response and sensitization to immune checkpoint blockade, but the molecular mechanisms involved remain largely unknown. Here, we show that following ionizing radiation (IR), macrophages accumulate single and double strand-DNA breaks and fragmented mitochondria in their cytosol, and stabilize the DNA sensor cyclic GMP-AMP synthase (cGAS). We demonstrate that mitochondrial fragmentation is induced by the activation of the dynamin-related protein 1 (DRP1), and controls the stabilization of cGAS and the proinflammatory activation of irradiated macrophages. Furthermore, pharmacological and genetic inhibitions of cGAS impair the proinflammatory activation of irradiated macrophages, thus revealing that cGAS is a central effector of IR-mediated proinflammatory macrophage activation. Interestingly, we also report that the purinergic receptor P2Y2 acts as an endogenous repressor of the proinflammatory macrophage activation and demonstrate that P2Y2 inactivation enhances the capacity of irradiated macrophages to undergo a proinflammatory activation. Our results thus define a new signaling pathway elicited in macrophages by IR directing mitochondrial dynamics, cytosolic DNA recognition by cGAS and proinflammatory phenotype, which is enhanced following P2Y2 inactivation.

immunology↗

Transgene-free hematopoietic stem and progenitor cells from human induced pluripotent stem cells

Introductory paragraphThe successful production of Hematopoietic Stem and Progenitor Cells (HSPCs) from human pluripotent sources is conditioned by transgene delivery1-5. We describe here a dedicated and tractable one step, GMP-grade, transgene-free and stroma-free protocol to produce HSPCs from human induced pluripotent stem cells (hiPSCs). This procedure, applied to several sources of hiPSCs with equal efficiency, is based on a directed differentiation with morphogens and cytokines to generate a cell population close to nascent HSPCs or their immediate forerunners i.e., hemogenic endothelial cells6-9. Following engraftment into immunocompromised recipients, this cell population was proved capable of a robust myeloid, lymphoid and definitive red blood cell production in sequential recipients for at least 40 weeks. Further identification of the repopulating cells show that they express the G protein-coupled receptor APELIN (APLNR) and the homing receptor CXCR4. This demonstrates that the generation of bona fide HSPCs from hiPSCs without transgenes is possible and passes through an early endo-hematopoietic intermediate. This work opens the way to the generation of clinical grade HSPCs for the treatment of hematological diseases and holds promise for the analysis of HSPC development in the human species.

cell biology↗